Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III disappointment for GSK/Tolerx-partnered drug follows last fall's Phase III miss by Lilly and MacroGenics' anti-CD3 antibody in same indication.

You may also be interested in...



GSK Highlights R&D Productivity Gains In First Quarter

Although GlaxoSmithKline's global sales declined by 10% and EPS rose by 9% during the first quarter, the UK Big Pharma sees signs of increased R&D productivity.

GSK Highlights R&D Productivity Gains In First Quarter

Although GlaxoSmithKline's global sales declined by 10% and EPS rose by 9% during the first quarter, the UK Big Pharma sees signs of increased R&D productivity.

GSK Announces Share Buyback Program As Pretax Profits Fall By 52% In 2010

GlaxoSmithKline plans to divest non-core OTC brands this year as CEO describes 2010 as a challenging year.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071946

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel